Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Antiviral Therapy Année : 2019

Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.

Antoine Frangeul
  • Fonction : Auteur
Cécile Bussetta
  • Fonction : Auteur
Jérôme Deval
  • Fonction : Auteur

Résumé

In the treatment of HIV, the loose active site of the HIV-1 reverse transcriptase (RT) allows numerous nucleotide analogues to act as proviral DNA 'chain-terminators'. Acyclic nucleotide phosphonate analogues (ANPs) represent a particular class of nucleotide analogue that does not possess a ribose moiety. The structural basis for their substrate efficiency regarding viral DNA polymerases is poorly understood.
Fichier non déposé

Dates et versions

hal-02061712 , version 1 (08-03-2019)

Identifiants

  • HAL Id : hal-02061712 , version 1
  • PUBMED : 18389906

Citer

Antoine Frangeul, Cécile Bussetta, Jérôme Deval, Karine Barral, Karine Alvarez, et al.. Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues.. Antiviral Therapy, 2019, 13 (1), pp.115-24. ⟨hal-02061712⟩
29 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More